Pfizer shares faced downward pressure as the company struggled with a persistent decline in demand for its COVID-19 portfolio. The pharmaceutical giant reported that weakening sales of its pandemic-era treatments heavily weighed on quarterly results, underscoring the ongoing challenge of transitioning to a post-pandemic growth strategy.

Pricing Pressures in Obesity Care

In Denmark, Novo Nordisk saw its shares plunge following a cautious financial forecast. The drugmaker warned investors that anticipated price reductions for its flagship treatments, Ozempic and Wegovy, in the U.S. market will likely impact revenue by 2026. According to the company report, these pricing adjustments are expected to drag sales 5% to 13% lower than 2025 levels, which are projected at approximately 309.06 billion Danish kroner ($48.79 billion).

Bucking the downward trend, Merck reported robust quarterly growth driven by a diversified portfolio. The company attributed its gains to:

• Sustained demand for oncology treatments.
• Growth in the respiratory drug segment.
• Increased sales of cardiometabolic medications.